E Zine Header Image

We'd like to share all our latest news with you. Do get in touch if you'd like to talk to us about any of these stories, or if you have an exciting innovation of your own.

Fold the Future

7a534ea2 4ec7 Cc17 3095 C642e8a56c44

Sibylla Biotech is developing a highly differentiated approach in the field of protein degradation. It is developing small molecule compounds designed to target proteins during the folding process. By binding to the folding intermediate states, Sibylla can access a range of targets previously considered undruggable. Seroba is delighted to add Sibylla to our Portfolio of investee companies, with Bruno Montanari joining the Board. Sibylla has just announced the successful close of its €23 million Series A financing round Read more

Jeanne Bolger joins our team

We are delighted to welcome Dr Jeanne Bolger as a Venture Partner with Seroba. A graduate of UCD, Jeanne has over 35 years of pharmaceutical industry experience. She spent 11 years in licensing and acquisition, including as Global Head of Scientific Licensing for Johnson & Johnson's Pharmaceutical business and before that as Director in the Business Development Group at GlaxoSmithKline. As Vice President Venture Investment in J&J's corporate venture fund, Jeanne spent 10 years leading investments in life science start-ups across Europe. Read more

7cd4c84a C69e 2e2a 71e5 6bc563e77d80

Celebrating 400 times!

C2aed962 536c 4763 5d2a 298df064ee04

Endotronix has celebrated the successful implantation of the 400th Cordella™ Pulmonary Artery (PA) Pressure Sensor. The Cordella System is designed to enable scalable remote heart failure management that combines patient engagement and optimal medication titration to improve care and prevent worsening heart failure. The company also recently announced publication of the PROACTIVE-HF trial design rationale, the first global Investigational Device Exemption (IDE) trial for PA pressure-guided heart failure management, in the 'Journal of Cardiac Failure'. Read more

When Every Minute Counts

For patients who suffer a stroke event, the faster they are treated the better as 'time is brain'. Galway-based company, Perfuze, has closed a Series A financing of €22.5M, to complete the clinical evaluation and regulatory clearance of its next-generation Millipede technology. Millipede is designed for rapid and successful blood vessel recanalization, vital to improve a patient’s functional status and reduce mortality following a stroke. Daniel O'Mahony has joined the board. Read more

997db760 0051 F7dd D380 9f332b9db6df

Dennis Purcell Joins Shorla Oncology as Chairman

Bcd385d5 Be3e 9d17 F6e9 Ca06e8083321

A leader in the biotech industry, Dennis Purcell brings significant experience that will help guide Seroba's Portfolio company, Shorla, in bringing their novel oncology products to the U.S. market. Mr Purcell is a leading life science investor and a veteran of the biotech industry.  Read more

Storming Ahead

STORM Therapeutics (STORM), the leader in the field of RNA modifying enzymes, is becoming a clinical stage company, led by a new CEO.
STORM is discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases. The company has recently announced the appointment of Dr. Jerry McMahon as President and Chief Executive Officer and Board Director. Read more

3e14a5c7 Cb87 45c9 Bf1d 87df44d5422d

AIB StartUp Clinic

Fd6bf118 A69d 90b1 D047 Aad657dba766

Seroba and Allied Irish Bank (AIB) will be at the Portershed in Galway for the AIB StartUp Clinic in October. This will be the first face-to-face AIB StartUp Clinic since before the pandemic. Jennifer McMahon and Alan O'Connell will meet with start-up teams eager to discuss their innovations, gain experience in pitching to VCs and find out how best to raise finance to support their product development. If you'd like a chat-slot at the AIB StartUp Clinic, then find out more here.

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top